InMed reduces exercise price of Sabby and Wainwright preferred investment options to $0.80

InMed Pharmaceuticals Inc.

Sabby options now exercisable at $0.80 (was $2.436) for up to 2,151,478 shares.
Wainwright options exercise price reduced to $0.80 from $82.50, $20.75, and $3.2013 for 153,236 shares.
Amendments signed April 21 and April 24, 2026; announced April 27.
Lower exercise price could lead to exercise and dilution of existing shareholders.

item 1.01item 3.03item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.